MRK merck’s lipfendra® (enlicitide) is the first and only once-daily oral pcsk9 inhibitor approved by the U.S. FDA to reduce ldl-c in adults
MRK merck’s lipfendra® (enlicitide) is the first and only once-daily oral pcsk9 inhibitor approved by the U.S. FDA to reduce ldl-c in adults with hypercholesterolemia
Story updates
10:50:15 AM UTC
SquawkNews
Merck announced the FDA...
MRK merck’s lipfendra® (enlicitide) is the first and only once-daily oral pcsk9 inhibitor approved by the U.S.
FDA to reduce ldl-c in adults with hypercholesterolemia